1. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs
- Author
-
Shinpei Nonen, Masaki Kato, Yoshiteru Takekita, Masataka Wakeno, Toshihiko Kinoshita, Junichi Azuma, Alessandro Serretti, Kato, M, Serretti, A., Nonen, S., Takekita, Y., Wakeno, M., Azuma, J., and Kinoshita, T.
- Subjects
Cyclopropanes ,Male ,Oncology ,Fibroblast Growth Factor ,Fluvoxamine ,Sex Factor ,law.invention ,Japan ,Randomized controlled trial ,law ,Age Factor ,Serotonin Plasma Membrane Transport Proteins ,Age Factors ,Milnacipran ,Cyclopropane ,Middle Aged ,Psychiatric Status Rating Scale ,Paroxetine ,Antidepressive Agents ,Psychiatry and Mental health ,Treatment Outcome ,Schizophrenia ,Receptor, Serotonin, 5-HT1A ,Antidepressive Agent ,Antidepressive Agents, Second-Generation ,Major depressive disorder ,Original Article ,Female ,Psychology ,Serotonin Plasma Membrane Transport Protein ,Human ,medicine.drug ,Clinical psychology ,medicine.medical_specialty ,Cellular and Molecular Neuroscience ,Sex Factors ,Receptors, Adrenergic, alpha-2 ,Rating scale ,Internal medicine ,medicine ,Humans ,Biological Psychiatry ,Psychiatric Status Rating Scales ,Depressive Disorder, Major ,medicine.disease ,Fibroblast Growth Factors ,Pharmacogenetics - Abstract
Pharmacogenetics may allow for a personalized treatment, but a combination with clinical variables may further enhance prediction. In particular, in the present paper, we investigated early partial improvement (EPI) defined as 20% or more improvement by rating scales 2weeks after treatment, in combination with selected gene variants as a predictor of treatment outcome in patients with major depressive disorder. Two randomized controlled trials with 168 Japanese depressed patients were used. A stepwise multiple linear regression model with HAM-D score change at week 6 as the dependent variable and genotypes, EPI, baseline HAM-D score, age and sex as independent variables was performed in paroxetine, fluvoxamine and milnacipran, respectively, to estimate the prediction of HAM-D change at week 6. In the paroxetine sample, only EPI (P
- Published
- 2015